### **OMICS** Journals are welcoming Submissions

OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.
OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: <u>http://omicsonline.org/Submitmanuscript.php</u>

Yasuhiro Kuramitsu, M.D., Ph.D Associate Professor Departments of Biochemistry and Functional Proteomics Yamaguchi University Graduate School of Medicine, Ube, Japan E-mail: climates@yamaguchi-u.ac.jp Pancreatic cancer remains one of the diseases with poor prognosis, and the most patients have no chance to be operated when they are diagnosed as pancreatic cancer. Their 5-year survival rate is less than 5%. Gemcitabine is one of the most effective chemotherapeutic drugs for pancreatic cancer, but the therapeutic effect is insufficient because many types of pancreatic cancer are resistant. We have reported that *HSP27 was one of the important factors related to gemcitabine-resistance*. We treated gemcitabine-resistant pancreatic cancer cells with interferon-gamma or KNK-437, which were reported as HSP27-suppressors, and showed the suppressive effects of HSP27 and combinatorial effects on inhibition of proliferation against gemcitabineresistant pancreatic cancer cells.

AHCC is an extract of basidiomycete mushroom and includes polysaccharide, and has been used as health food to enhance the therapeutic effects and reduce the adverse effects of chemotherapy. In the present study we *investigated the effects of AHCC on the expression of HSP27, and the effects of combinatorial treatment of AHCC and gemcitabine on the gemcitabineresistant pancreatic cancer cells*, and AHCC down-regulated HSP27 and showed an anti-proliferative effect on gemcitabine-resistant cells.

## **Prognosis of pancreatic cancer**

JPS-stage at the time of diagnosis

Therapy and prognosis

Stage	n	5 year survival rate	Method of therapy	5 year survival rate
Stage I	128	58.6%	Resection	12.2%
Stage II	192	51.0%	Palliative	0%
Stage III	1039	25.9%	operation	
StageIVa	1809	11.9%	Laparotomy	2.0%
StageIVb	4661	2.8%	Non- operation	0%

SUIZOU 2003 (Japanese).

# Gemcitabine(gemzar, GEM), a drug used for chemotherapy against pancreatic cancer



Gemcitabine Metabolism

Figure from Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, Saif MW, JOP. J Pancreas (Online) 2006; 7:337-348.

## Materials 1 : Pancreatic cancer cell lines

	differentiated	origin
MiaPaCa-2	undifferentiated	pancreas
Panc-1	undifferentiated	pancreas
BxPC-3	poorly diff.	pancreas
AsPC-1	moderately diff.	ascites
PK45p	unknown	pancreas
PK59	unknown	pancreas

The cytotoxicity of gemcitabine (GEM) to the cells was evaluated by MTT assay



### 2-DE pattern of MiaPaCa-2 (sensitive) and PK59 (resistant)

### MiaPaCa-2 (GEM-sensitive)

### PK-59 (GEM-resistant)



Mol Med Rep. 2008 May-Jun;1(3):429-34.

## **Expression analysis of HSP27 (2DE)**







Mol Med Rep. 2008 May-Jun;1(3):429-34.

## **Immunoblot analysis of HSP27**



Mol Med Rep. 2008 May-Jun;1(3):429-34.

### Materials 2 : Acquired resistant cell line to gemcitabine

#### SELENOPROTEIN P, AS A PREDICTOR FOR EVALUATING GEMCITABINE RESISTANCE IN HUMAN PANCREATIC CANCER CELLS

Shin-ichiro MAEHARA<sup>1\*</sup>, Shinji TANAKA<sup>1</sup>, Mitsuo Shimada<sup>1</sup>, Ken Shirabe<sup>1</sup>, Yoshiro Sarto<sup>2</sup>, Kazuhiko Takahashi<sup>3</sup> and Yoshihiko MAEHARA<sup>1</sup>

<sup>1</sup>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan <sup>2</sup>National Institute of Advanced Industrial Science and Technology, Human Stress Signal Research Center, Osaka, Japan <sup>3</sup>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan



Int J Oncol. 2007 Dec;31(6):1345-50

### **Expression of HSP 27 in KLM1 and KLM1-R**

# KLM1KLM1-RHSP27actin

Int J Oncol. 2007 Dec;31(6):1345-50

### Decreasing resistance to GEM in HSP27knocked down KLM1-R cells



# The immunopositive rate of HSP27 in progressive disease(PD) and stable disease(SD)



Int J Oncol. 2007 Dec;31(6):1345-50

### Survival Curves of Pancreatic Cancer Patients (HSP27-positive and HSP27-negative) treated with GEM(Kaplan-Meier)



Int J Oncol. 2007 Dec;31(6):1345-50

### **Active Hexose-Correlated Compound(AHCC)**



Active hexose-correlated compound (AHCC), an extract of basidiomycete mushroom called Lentinula edodes, is composed of polysaccharides, amino acids, lipids and minerals. The predominant components of AHCC are oligosaccharides and their major portions are 5 kDa molecules named  $\alpha$ 1,4-glucans. AHCC is used as a health food to support the therapeutic effects and alleviate adverse effect of chemotherapy owing to immunomodulatory and antitumor effects of AHCC.

# **Expression levels of HSP family proteins in KLM1-R cells treated with AHCC.**



Anticancer Res. 2014 Jan;34(1):141-6

# The intensity of the HSP27/actin bands in KLM1-R cells treated with AHCC.



Anticancer Res. 2014 Jan;34(1):141-6

### **Cytotoxic effect of AHCC on KLM1-R cells.**



Anticancer Res. 2014 Jan;34(1):141-6

### The cytotoxic effect of the combinatorial treatment of AHCC and GEM on KLM1-R cells.



Anticancer Res. 2014 Jan;34(1):141-6



Anticancer Res. 2014 (in press)

### **Expression levels of SOX2 in KLM1-R cells-2**



SITY

### Journal of Proteomics & Bioinformatics Related Journals

Transcriptomics: Open Access

Journal of Pharmacogenomics & Pharmacoproteomics

Journal of Data Mining in Genomics & Proteomics



For more details on Conferences Related Journal of Proteomics & Bioinformatics please visit:

http://www.conferenceseries.com/biochemi stry-meetings Open Access Membership with OMICS International enables academicians, research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors. For more details and benefits, click on the link below:

http://omicsonline.org/membership.php